Third quarter revenue for the Company's proton beam radiation therapy system increased 4.4% to $2,316,000 compared to revenue ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to ...

SMid Biotech Analyst Joseph holds a conference call with CEO Evans on November 12 at 2 pm hosted by JPMorgan.Webcast Link Published first on ...

In March, CBS 42 reported on a man trapped in a U-Haul truck under a concrete beam at the Courtland Vesta Apartment Complex ...

Leerink Partners has recently raised Beam Therapeutics Inc (BEAM) stock to Outperform rating, as announced on November 6, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had ...

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM.

Radiation therapy has been used to treat cancer since the beginning of the 20th century. This type of treatment continues to be one of the most effective treatments for cancerous (malignant) and ...

Through partnership with Legion Healthcare Partners, proton therapy system will target tumors without "exit radiation" ...

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.

The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular degeneration.

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had ...